U.K. researchers driven out by tough regulations

A set of tough new government regulations governing drug trials in the U.K. has begun to drive some clinical trials out of the country. New data suggests the some trials have been delayed or moved abroad while other developers expressed concern over the future of drug research. Analysts say that the government's regulatory response to an earlier clinical trial disaster will seriously damage the U.K.'s efforts to encourage more research.

The Financial Times reports that in the wake of the TeGenero's TGN1412 trial disaster, which left six volunteers in the hospital, regulators have approved only one of four high-risk trial to proceed after re-reviewing their programs. Only one of eight other high-risk trials subsequently submitted for regulatory approval has been given a green light.

- read the article on the U.K. trial dilemma from the Financial Times

Related Articles:
GSK looks abroad for more scientists as U.K. shortage grows. Report
New report claims signs of bay area brain drain. Report
TeGenero trial disaster leads to regulatory reviews. Report
Trial disaster triggers biotech bankruptcy. Report

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.